A practical reference on post-marketing surveillance: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-18. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
The recommended daily allowance (RDA) of methionine (combined with cysteine) for adults is set at 13–14 mg kg-1 day-1 (13–14 mg per kg of body weight per day), but some researchers have argued that this figure is too low, and should more appropriately be 25 mg kg-1 day-1. Despite the importance of sulfur, restrictions of dietary sulfur are sometimes recommended for certain diseases and for other reasons.
The crew landed on the reciprocal runway with no further incident. No casualties. On September 21, 2001, RA-86074 (c/n 041) operating as Aeroflot Flight 521 belly-landed at Dubai after a flight from Moscow, the flight crew having switched off the ground proximity warning due to heavy workload on the approach and then neglected to extend the landing gear; no casualties; aircraft written off. On July 28, 2002, Pulkovo Aviation Enterprise Flight 9560 RA-86060 (c/n 027) crashed shortly after departure from Moscow on a repositioning flight to Saint Peterburg. The trim toggle button on the control column caused a spontaneous retrimming of the tailplane, rapid transition to nose-heavy trim and a dive. The four flightdeck crew, two ground support staff and ten cabin crew aboard the aircraft died, making the crash the deadliest aviation accident involving the Il-86. The two injured survivors were cabin crew members. Following the Moscow crash in July 2002, the MAK Interstate Aviation Committee withdrew the Il-86's certificate of airworthiness, temporarily grounding the type. The certificate was rapidly restored in stages by early 2003. The accident prompted the Egyptian civil aviation authorities to attempt to ban Il-86 operations to Egypt. Amid continuing negotiations, by 2007 the intention had lapsed, with intensive Il-86 operations to and from Egypt continuing.
Knockout mutants for FUT4 and FUT6 showed severe inhibition in root growth under salt conditions while knockout mutants for GlcAT14A, GlcAT14B, and GlcAT14C showed enhanced cell elongation rates in dark grown hypocotyls and light grown roots during seedling growth. In the case of ray1 mutant seedlings grown on vertical plates, the length of the primary root was affected by RAY1 mutation. In addition, the primary root of ray1 mutants grew with a slower rate compared to wild-type Arabidopsis. Taken together, these studies provide evidence that proper glycosylation of AGPs is important to AGP function in plant growth and development.
Sources: en.wikipedia.org
== Efficacy and side effects == Counterintuitively to the drastic effect of thinly winged insect-venom on neurological processes, some toxins of these hymenopteran insects are used in the field of medicine. An example can be found in tertiapin-Q from the European honey bee (Apis mellifera) which is used in the treatment of pain, multiple sclerosis (MS), and rheumatoid arthritis. The spider wasp is also a hymenopteran insect but its pompilidotoxins are currently not linked to any existing drugs. Therefore there are also no indications for these compounds. PMTXs medical potential has been considered in the past but to no avail. Their possible characteristic to only enhance neuronal activity has already been nullified as early as in 1998 by Harsch et.al who experimentally found that α-PMTX could also disrupt the activity of rat cortical neurons irreversibly and immediately upon administration. The unpredictability of the toxin and the still rather large gap in information on the toxin, contribute to it not having been translated into medicine. However, even though pompilidotoxins are not used as drugs, they do hold a large medical value. This value comes forth from the fact that this neurotoxin of 13 amino acids is so much smaller than its fellow sodium channel-specific polypeptide toxins. For example, pompilidotoxins are much smaller than the conventionally studied sea anemone toxin that has 46 to 49 amino acids, or the α-scorpion toxin of even 60 to 65 residues.
== External links == skel&wallsabd at The Anatomy Lesson by Wesley Norman (Georgetown University) "Anatomy photo:35:os-0108". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. (before removing skin) "Anatomy photo:35:06-0101". SUNY Downstate Medical Center. Archived from the original on March 5, 2016. (after removing skin) "Anatomy diagram: 03281.000-2". Roche Lexicon - illustrated navigator. Elsevier. Archived from the original on 2014-01-01.
=== Toxicology === Mitragynine toxicity in humans is largely unknown, as animal studies show significant species-specific differences in mitragynine tolerance. Mitragynine toxicity in humans is rarely reported although specific examples of seizures and liver toxicity in kratom consumers have been reported. Due to cytochrome P450 enzyme inhibition, the combination of mitragynine with other drugs poses concern for adverse reactions to mitragynine. Fatalities involving mitragynine tend to include its use in combination with opioids and some cough suppressants. Post-mortem toxicology screens indicate a wide range of mitragynine blood concentrations ranging from 10 μg/L to 4800 μg/L, making it difficult to calculate what constitutes a toxic dose in humans. These variations are suggested to result from differences in the toxicology assays used, and how long after death the assays were conducted.
Gluten exorphins are a group of opioid peptides formed during the digestion of the gluten protein. These peptides work as external regulators for gastrointestinal movement and hormonal release. The breakdown of gliadin, a polymer of wheat proteins, creates amino acids that stop the gluten epitopes from entering the immune system to activate inflammatory reactions. During this process, gluten does not fully break down, thus increasing the presence of gluten exorphins. Because of this, researchers think this is what might lead to various diseases. Research shows the benefits of gluten- and casein-free diets for people with diseases and disorders connected to gluten exorphins. The mechanism behind this is still unknown. There is a possibility that gluten has deleterious effects on the human digestive system. When people are more susceptible to gluten and casein allergies, the weakened intestinal lining allows gluten exorphin to flow.
Sources: en.wikipedia.org
1833: English phycologists Amelia Griffiths and Mary Wyatt published two books on local British seaweeds. Griffiths had an internationally respected reputation as a skilled seaweed collector and scholar, and Swedish botanist Carl Agardh had earlier named the seaweed genus Griffithsia in her honour. 1833: American botanical and scientific illustrator Orra White Hitchcock was best known for illustrating the scientific works of her husband, geologist Edward Hitchcock (1793–1864), but was also notable for her own artistic and scientific work. The most well known appear in her husband's seminal works, the 1833 Report on the Geology, Mineralogy, Botany, and Zoology of Massachusetts and its successor, the 1841 Final Report produced when he was State Geologist. For the 1833 edition, Pendleton's Lithography (Boston) lithographed nine of Hitchcock's Connecticut River Valley drawings and printed them as plates for the work. In 1841, B. W. Thayer and Co., Lithographers (Boston) printed revised lithographs and an additional plate. The hand-colored plate "Autumnal Scenery. View in Amherst" is Hitchcock's most frequently seen work. 1835: Scottish polymath Mary Somerville and German astronomer Caroline Herschel were elected the first female members of the Royal Astronomical Society. 1836: Early English geologist and paleontologist Etheldred Benett, known for her extensive collection of several thousand fossils, was appointed a member of the Imperial Natural History Society of Moscow.
Genetic testing for Huntington's disease has raised several ethical issues, which include defining how mature an individual should be before being considered eligible for testing, ensuring the confidentiality of results, and deciding whether companies should be allowed to use test results for decisions on employment, life insurance or other financial matters. There was controversy when Charles Davenport proposed in 1910 that compulsory sterilization and immigration control be used for people with certain diseases, including HD, as part of the eugenics movement. In vitro fertilization has some issues regarding its use of embryos. Some HD research has ethical issues due to its use of animal testing and embryonic stem cells. The development of an accurate diagnostic test for HD has caused social, legal, and ethical concerns over access to and use of a person's results. Many guidelines and testing procedures have strict procedures for disclosure and confidentiality to allow individuals to decide when and how to receive their results and also to whom the results are made available. Insurance companies and businesses are faced with the question of whether to use genetic test results when assessing an individual, such as for life insurance or employment. The United Kingdom's insurance companies agreed with the Department of Health and Social Care that until 2017 customers would not need to disclose predictive genetics tests to them, but this agreement explicitly excluded the government-approved test for Huntington's when writing policies with a value over £500,000.
During the induction phase, electrolyte levels, glucose, blood counts, and liver and kidney function should be tested twice a week. In the consolidation phase, these tests should be performed weekly. Caution is advised in patients with kidney failure. During arsenic trioxide treatment, women of childbearing age and men capable of fathering children should use effective contraception. The impact of arsenic trioxide on fertility has not been thoroughly studied.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.